基于体素分析识别预测前列腺癌放疗后泌尿毒性反应的尿道膀胱亚区
本研究对272例接受调强放疗/影像引导放疗的前列腺癌患者进行前瞻性分析,通过体素分析识别与急性和晚期泌尿症状相关的尿道膀胱亚区。研究发现尿道及膀胱后部、上部的剂量可预测急性尿失禁、急性尿潴留及晚期尿潴留、排尿困难、血尿,亚区预测能力优于全膀胱剂量体积直方图。
要点
- 尿道剂量与急性尿失禁相关,膀胱三角区剂量与急性尿潴留相关。
- 膀胱后部剂量与晚期尿潴留和排尿困难相关,膀胱上部剂量与晚期血尿相关。
- 亚区剂量预测毒性的ROC曲线下面积最高达0.81(晚期排尿困难),优于全膀胱DVH。
核心结论
- 尿道及膀胱后部和上部的剂量可预测急性尿失禁、急性尿潴留以及晚期尿潴留、排尿困难和血尿。
- 全膀胱剂量具有中等预测能力。
研究设计与样本
- 前瞻性分析272例接受调强放疗/影像引导放疗的前列腺癌患者。
- 将每例患者CT图像经非刚性配准空间归一化至共同坐标系,并将剂量映射至该坐标系。
- 采用基于体素的统计分析生成不同泌尿症状的三维剂量-体积图,识别有或无毒性患者间剂量差异显著的亚区。
- 将各亚区回传至个体原始空间,计算亚区及全膀胱的剂量体积直方图,并用逻辑回归和Cox回归比较亚区与全膀胱的预测能力。
主要发现
- 膀胱和尿道存在局部剂量效应关系。
- 识别出5种症状的亚区:急性尿失禁位于尿道,急性尿潴留位于膀胱三角区,晚期尿潴留和排尿困难位于膀胱后部,晚期血尿位于膀胱上部,有或无毒性患者间剂量差异范围为1.2至9.3 Gy。
- 亚区剂量对毒性反应具有显著预测作用,最大ROC曲线下面积分别为:急性尿失禁0.73,急性尿潴留0.62,晚期尿潴留0.70,晚期排尿困难0.81,晚期血尿0.67。
- 全膀胱DVH仅对晚期尿潴留、排尿困难和血尿具有预测能力(曲线下面积0.65-0.72)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To apply a voxel-based analysis to identify urethrovesical symptom-related subregions (SRSs) associated with acute and late urinary toxicity in prostate cancer radiation therapy. METHODS AND MATERIALS: Two hundred seventy-two patients with prostate cancer treated with intensity-modulated radiation therapy/image-guided radiation therapy were analyzed prospectively. Each patient's computed tomography imaging was spatially normalized to a common coordinate system via nonrigid registration. The obtained deformation fields were used to map the dose of each patient to the common coordinate system. A voxel-based statistical analysis was applied to generate 3-dimensional dose-volume maps for different urinary symptoms, allowing the identification of corresponding SRSs with statistically significant dose differences between patients with or without toxicity. Each SRS was propagated back to each individual's native space, and dose-volume histograms (DVHs) for the SRSs and the whole bladder were computed. Logistic and Cox regression were used to estimate the SRS's prediction capability compared with the whole bladder. RESULTS: A local dose-effect relationship was found in the bladder and the urethra. SRSs were identified for 5 symptoms: acute incontinence in the urethra, acute retention in the bladder trigone, late retention and dysuria in the posterior part of the bladder, and late hematuria in the superior part of the bladder, with significant dose differences between patients with and without toxicity, ranging from 1.2 to 9.3 Gy. The doses to the SRSs were significantly predictive of toxicity, with maximum areas under the receiver operating characteristic curve of 0.73 for acute incontinence, 0.62 for acute retention, 0.70 for late retention, 0.81 for late dysuria, and 0.67 for late hematuria. The bladder DVH was predictive only for late retention, dysuria, and hematuria (area under the curve, 0.65-0.72). CONCLUSIONS: The dose delivered to the urethra and the posterior and superior parts of the bladder was predictive of acute incontinence and retention and of late retention, dysuria, and hematuria. The dose to the whole bladder was moderately predictive.
引用
- Mylona E, Acosta O, Lizee T, et al. Voxel-Based Analysis for Identification of Urethrovesical Subregions Predicting Urinary Toxicity After Prostate Cancer Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019. PMID: 30716523. doi:10.1016/j.ijrobp.2019.01.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。